Kiley Juergens Wealth Management LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Kiley Juergens Wealth Management LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 24.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,429 shares of the biopharmaceutical company’s stock after selling 6,077 shares during the quarter. Kiley Juergens Wealth Management LLC’s holdings in Pfizer were worth $531,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Worth Asset Management LLC acquired a new position in Pfizer during the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer during the 3rd quarter worth approximately $30,000. GoalVest Advisory LLC increased its holdings in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in Pfizer during the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC increased its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.8 %

Pfizer stock traded down $0.22 during mid-day trading on Tuesday, hitting $25.69. The company’s stock had a trading volume of 28,601,821 shares, compared to its average volume of 42,553,457. The firm’s 50 day moving average is $27.27 and its 200 day moving average is $28.84. The company has a market cap of $145.47 billion, a PE ratio of 71.69, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $41.33.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.14 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.